RT Journal Article
SR Electronic
A1 Butterman, Eric
T1 CXA-201 Effective against Common ICU Pathogens, Including MDR Gram-Negative Pathogens and Pseudomonas aeruginosa
JF MD Conference Express
YR 2011
FD SAGE Publications
VO 11
IS 12
SP 10
OP 11
DO 10.1177/155989771112005
UL http://mdc.sagepub.com/content/11/12/10.abstract
AB Using a pharmacokinetic/pharmacodynamic (PK/PD) target algorithm, the in vitro potency of CXA-201 (CXA101/tazobactam), a novel cephalosporin and b-lactamase inhibitor combination that is being developed to treat serious bacterial infections, was reported to be lower in isolates from the intensive care unit (ICU) compared with non-ICU isolates.